130 related articles for article (PubMed ID: 11506480)
1. Immunohistochemical detection of Fas and Fas ligand in sarcomatoid renal cell carcinoma.
Leroy X; Wacrenier A; De la Taille A; Gosset P; Saint F; Biserte J; Gosselin B
APMIS; 2001 Jun; 109(6):469-73. PubMed ID: 11506480
[TBL] [Abstract][Full Text] [Related]
2. Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: a systematic study of 19 immunohistochemical markers in 42 cases.
Yu W; Wang Y; Jiang Y; Zhang W; Li Y
BMC Cancer; 2017 Apr; 17(1):293. PubMed ID: 28449664
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
4. Adult renal cell carcinoma with rhabdoid differentiation: incidence and clinicopathologic features in Chinese patients.
Yang X; Xi C; Jin J; Zhou L; Su J; Liu L; Liu Y
Ann Diagn Pathol; 2015 Apr; 19(2):57-63. PubMed ID: 25708024
[TBL] [Abstract][Full Text] [Related]
5. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors.
Kim YS; Kim KH; Choi JA; Lee JH; Kim HK; Won NH; Kim I
Arch Pathol Lab Med; 2000 May; 124(5):687-93. PubMed ID: 10782148
[TBL] [Abstract][Full Text] [Related]
6. Sarcomatoid renal cell carcinoma. A study of its proliferative activity.
Oda H; Machinami R
Cancer; 1993 Apr; 71(7):2292-8. PubMed ID: 8095849
[TBL] [Abstract][Full Text] [Related]
7. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract][Full Text] [Related]
8. Sarcomatoid renal cell carcinoma. An immunohistochemical study of 18 cases.
DeLong W; Grignon DJ; Eberwein P; Shum DT; Wyatt JK
Arch Pathol Lab Med; 1993 Jun; 117(6):636-40. PubMed ID: 7684893
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma.
Tickoo SK; Alden D; Olgac S; Fine SW; Russo P; Kondagunta GV; Motzer RJ; Reuter VE
J Urol; 2007 Apr; 177(4):1258-63. PubMed ID: 17382701
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathological features and prognosis of renal cell carcinoma with sarcomatoid differentiation].
Jiang Y; Su G; Yu W; Li J; Lu Q; Li Y; Zhang W
Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):823-6. PubMed ID: 26887511
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry and lectin histochemistry in sarcomatoid renal cell carcinoma: a comparison with classical renal cell carcinoma.
Harris SC; Hird PM; Shortland JR
Histopathology; 1989 Dec; 15(6):607-16. PubMed ID: 2606455
[TBL] [Abstract][Full Text] [Related]
12. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
13. [The evaluation of Fas/Fas ligand system in renal cell carcinoma--the effect of preoperative interferon-alpha therapy].
Sejima T; Miyagawa I
Nihon Hinyokika Gakkai Zasshi; 1999 Oct; 90(10):826-32. PubMed ID: 10565161
[TBL] [Abstract][Full Text] [Related]
14. Expression of apoptotic regulatory molecules in renal cell carcinoma: elevated expression of Fas ligand.
Olive C; Cheung C; Nicol D; Falk MC
Immunol Cell Biol; 1999 Feb; 77(1):11-8. PubMed ID: 10101681
[TBL] [Abstract][Full Text] [Related]
15. Sarcomatoid renal cell carcinoma: the chromophobe connection.
Akhtar M; Tulbah A; Kardar AH; Ali MA
Am J Surg Pathol; 1997 Oct; 21(10):1188-95. PubMed ID: 9331291
[TBL] [Abstract][Full Text] [Related]
16. The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma.
Sejima T; Iwamoto H; Morizane S; Hinata N; Yao A; Isoyama T; Saito M; Takenaka A
Urol Oncol; 2013 Oct; 31(7):1343-9. PubMed ID: 22153754
[TBL] [Abstract][Full Text] [Related]
17. Expression of Fas in renal cell carcinoma.
Horie S; Kano M; Higashihara E; Moriyama N; Tanaka E; Hirose A; Kakizoe T; Kawabe K
Jpn J Clin Oncol; 1997 Dec; 27(6):384-8. PubMed ID: 9437999
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of p53 and bcl-2 proteins is not associated with sarcomatoid change in renal cell carcinoma.
Kanamaru H; Li B; Miwa Y; Akino H; Okada K
Urol Res; 1999 Jun; 27(3):169-73. PubMed ID: 10422817
[TBL] [Abstract][Full Text] [Related]
19. Adult renal cell carcinoma with rhabdoid morphology represents a neoplastic dedifferentiation analogous to sarcomatoid carcinoma.
Chapman-Fredricks JR; Herrera L; Bracho J; Gomez-Fernandez C; Leveillee R; Rey L; Jorda M
Ann Diagn Pathol; 2011 Oct; 15(5):333-7. PubMed ID: 21665507
[TBL] [Abstract][Full Text] [Related]
20. Fine-needle aspiration cytology of sarcomatoid renal cell carcinoma: a morphologic and immunocytochemical study of 15 cases.
Auger M; Katz RL; Sella A; Ordóñez NG; Lawrence DD; Ro JY
Diagn Cytopathol; 1993; 9(1):46-51. PubMed ID: 8458282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
